A global pharmaceutical company was about to lose the strategic advantage of several blockbuster drugs coming off patent. In five years, the revenue shortfall would be significant. The senior commercial and scientific directors formed a “circle of leaders” comprised of 23 senior managers who had no meaningful history of collaboration on strategic initiatives. The hope was that the diversity of brainpower and perspectives would yield imaginative ways to outgrow the shortfall.